全文获取类型
收费全文 | 4002篇 |
免费 | 225篇 |
国内免费 | 42篇 |
专业分类
耳鼻咽喉 | 86篇 |
儿科学 | 97篇 |
妇产科学 | 56篇 |
基础医学 | 422篇 |
口腔科学 | 72篇 |
临床医学 | 429篇 |
内科学 | 1224篇 |
皮肤病学 | 44篇 |
神经病学 | 367篇 |
特种医学 | 111篇 |
外科学 | 561篇 |
综合类 | 13篇 |
预防医学 | 149篇 |
眼科学 | 72篇 |
药学 | 262篇 |
中国医学 | 3篇 |
肿瘤学 | 301篇 |
出版年
2023年 | 21篇 |
2022年 | 37篇 |
2021年 | 86篇 |
2020年 | 63篇 |
2019年 | 71篇 |
2018年 | 74篇 |
2017年 | 84篇 |
2016年 | 78篇 |
2015年 | 91篇 |
2014年 | 119篇 |
2013年 | 158篇 |
2012年 | 254篇 |
2011年 | 261篇 |
2010年 | 162篇 |
2009年 | 170篇 |
2008年 | 238篇 |
2007年 | 287篇 |
2006年 | 265篇 |
2005年 | 318篇 |
2004年 | 284篇 |
2003年 | 240篇 |
2002年 | 226篇 |
2001年 | 58篇 |
2000年 | 32篇 |
1999年 | 40篇 |
1998年 | 50篇 |
1997年 | 35篇 |
1996年 | 38篇 |
1995年 | 39篇 |
1994年 | 26篇 |
1993年 | 26篇 |
1992年 | 26篇 |
1991年 | 20篇 |
1990年 | 25篇 |
1989年 | 20篇 |
1988年 | 24篇 |
1987年 | 24篇 |
1986年 | 15篇 |
1985年 | 28篇 |
1984年 | 30篇 |
1983年 | 18篇 |
1982年 | 15篇 |
1981年 | 11篇 |
1980年 | 14篇 |
1978年 | 6篇 |
1976年 | 5篇 |
1975年 | 6篇 |
1973年 | 6篇 |
1972年 | 7篇 |
1971年 | 8篇 |
排序方式: 共有4269条查询结果,搜索用时 15 毫秒
101.
Napoli C Ackah E De Nigris F Del Soldato P D'Armiento FP Crimi E Condorelli M Sessa WC 《Proceedings of the National Academy of Sciences of the United States of America》2002,99(19):12467-12470
The effects of chronic treatment with nitric oxide-containing aspirin (NO-aspirin, NCX-4016) in comparison with regular aspirin or placebo on the development of a chronic disease such as atherosclerosis were investigated in hypercholesterolemic low-density lipoprotein (LDL)-receptor-deficient mice. Male mice were assigned randomly to receive in a volume of 10 ml/kg either placebo (n = 10), 30 mg/kg/day NO-aspirin (n = 10), or 18 mg/kg/day of regular aspirin (n = 10). After 12 weeks of treatment, the computer-assisted imaging analysis revealed that NO-aspirin reduced the aortic cumulative lesion area by 39.8 +/- 12.3% compared with that of the placebo (P < 0.001). Regular aspirin did not reduce significantly aortic lesions (-5.1 +/- 2.3%) compared with the placebo [P = 0.867, not significant (NS)]. Furthermore, NO-aspirin reduced significantly plasma LDL oxidation compared with aspirin and placebo, as shown by the significant reduction of malondialdehyde content (P < 0.001) as well as by the prolongation of lag-time (P < 0.01). Similarly, systemic oxidative stress, measured by plasma isoprostanes, was significantly reduced by treatment with NCX-4016 (P < 0.05). More importantly, mice treated with NO-aspirin revealed by immunohistochemical analysis of aortic serial sections a significant decrease in the intimal presence of oxidation-specific epitopes of oxLDL (E06 monoclonal antibody, P < 0.01), and macrophages-derived foam cells (F4/80 monoclonal antibody, P < 0.05), compared with placebo or aspirin. These data indicate that enhanced NO release by chronic treatment with the NO-containing aspirin has antiatherosclerotic and antioxidant effects in the arterial wall of hypercholesterolemic mice. 相似文献
102.
Pietro Ciccorossi Anna Maria Maina Filippo Oliveri Stefania Petruccelli Gioacchino Leandro Piero Colombatto Francesco Moriconi Franco Mosca Franco Filipponi Ferruccio Bonino Maurizia Rossana Brunetto 《Liver international》2007,27(5):612-619
BACKGROUND: Early identification of patients at a higher risk of rapidly progressive recurrent hepatitis post liver transplantation (LT) could help to tailor antiviral therapy. METHODS: We studied the correlation between early post-LT viral load and the histological and clinical outcomes of 49 consecutive patients (34 males, median age 55 years) in whom viraemia was monitored at days 0, 1, 7, 30, 180 and 365 after LT. RESULTS: Hepatitis C recurred at histology in 38 of 42 (90.5%) patients. Early viral load after LT was higher in patients with rapidly progressive hepatitis C recurrence (day 7 median HCV-RNA levels: 5.84 vs 4.93 Log(10) IU/ml, P=0.003). Day 7 HCV-RNA levels >/=2.5 x 10(5) IU/ml, donor age >60 years and rejection episodes were independently associated with progression to cirrhosis within one year post-LT [P=0.018, odds ratio (OR) 27.59; P=0.043, OR 13.85 and P=0.048, OR 9.95, respectively]. Day 7 viraemia and rejection episodes were independently associated with 5-years survival. Day 7 viraemia, in combination with acute hepatitis and/or donor age, showed 80% sensitivity, 94% specificity and 90.5% diagnostic accuracy to identify severe recurrence. CONCLUSIONS: Early post-LT HCV-RNA correlates with the severity of hepatitis C recurrence and in combination with donor age (>60 years) and rejections, identifies patients with a high risk of severe recurrence and candidates of cost-effective pre-emptive antiviral therapy. 相似文献
103.
104.
105.
Matias Trillini Monica Cortinovis Piero Ruggenenti Jorge Reyes Loaeza Karen Courville Claudia Ferrer-Siles Silvia Prandini Flavio Gaspari Antonio Cannata Alessandro Villa Annalisa Perna Eliana Gotti Maria Rosa Caruso Davide Martinetti Giuseppe Remuzzi Norberto Perico 《Journal of the American Society of Nephrology : JASN》2015,26(5):1205-1214
Secondary hyperparathyroidism contributes to post-transplant CKD mineral and bone disorder. Paricalcitol, a selective vitamin D receptor activator, decreased serum parathyroid hormone levels and proteinuria in patients with secondary hyperparathyroidism. This single-center, prospective, randomized, crossover, open-label study compared the effect of 6-month treatment with paricalcitol (1 μg/d for 3 months and then uptitrated to 2 µg/d if tolerated) or nonparicalcitol therapy on serum parathyroid hormone levels (primary outcome), mineral metabolism, and proteinuria in 43 consenting recipients of renal transplants with secondary hyperparathyroidism. Participants were randomized 1:1 according to a computer-generated sequence. Compared with baseline, median (interquartile range) serum parathyroid hormone levels significantly declined on paricalcitol from 115.6 (94.8–152.0) to 63.3 (52.0–79.7) pg/ml (P<0.001) but not on nonparicalcitol therapy. At 6 months, levels significantly differed between treatments (P<0.001 by analysis of covariance). Serum bone-specific alkaline phosphatase and osteocalcin decreased on paricalcitol therapy only and significantly differed between treatments at 6 months (P<0.001 for all comparisons). At 6 months, urinary deoxypyridinoline-to-creatinine ratio and 24-hour proteinuria level decreased only on paricalcitol (P<0.05). L3 and L4 vertebral mineral bone density, assessed by dual-energy x-ray absorption, significantly improved with paricalcitol at 6 months (P<0.05 for both densities). Paricalcitol was well tolerated. Overall, 6-month paricalcitol supplementation reduced parathyroid hormone levels and proteinuria, attenuated bone remodeling and mineral loss, and reduced eGFR in renal transplant recipients with secondary hyperparathyroidism. Long-term studies are needed to monitor directly measured GFR, ensure that the bone remodeling and mineral effects are sustained, and determine if the reduction in proteinuria improves renal and cardiovascular outcomes. 相似文献
106.
Cardiac regeneration. 总被引:5,自引:0,他引:5
Piero Anversa Annarosa Leri Jan Kajstura 《Journal of the American College of Cardiology》2006,47(9):1769-1776
The role and even the existence of new myocyte formation in the adult heart remain controversial. Documentation of cell cycle regulators, deoxyribonucleic acid synthesis, and mitotic images has only in part modified the view that myocardial growth can be accomplished exclusively from hypertrophy of an irreplaceable population of differentiated myocytes. However, myocyte regeneration and death occur physiologically, and these cellular processes are enhanced in pathologic states. These observations have challenged the view of the heart as a postmitotic organ and have proposed a new paradigm in which parenchymal and non-parenchymal cells are continuously replaced by newly formed younger populations of myocytes as well as by vascular smooth muscle and endothelial cells. Heart homeostasis is regulated by a stem cell compartment characterized by multipotent cardiac stem cells that possess the ability to acquire the distinct cell lineages of the myocardium. Similarly, adult bone marrow cells are able to differentiate into cells beyond their own tissue boundary and create cardiomyocytes and coronary vessels. This process has been termed developmental plasticity or transdifferentiation. Because of these properties, bone marrow cells and cardiac stem cells have been employed experimentally in the reconstitution of dead myocardium after infarction. These cell classes hold promise for the treatment of heart failure in humans. 相似文献
107.
108.
Cicoira M Rossi A Bonapace S Zanolla L Golia G Franceschini L Caruso B Marino PN Zardini P 《Journal of cardiac failure》2004,10(5):403-411
BACKGROUND: In chronic heart failure (CHF), changes in the extracellular space contribute to cardiac dysfunction. We aimed to determine whether aminoterminal-propeptide of type III procollagen (PIIINP), a marker of extracellular matrix turnover, might provide prognostic information in CHF patients. METHODS AND RESULTS: A total of 101 consecutive CHF patients (mean age 61.7 +/- 8.7 years, 88% males) were followed up between 1999 and 2001. The combined endpoint of the study was death and hospitalization for heart failure. During follow-up there were 15 deaths and 11 hospitalizations for worsening heart failure. At the survival analysis, age (P = .02), New York Heart Association class (P = .014), s-creatinine (P = .014), plasma-PIIINP (p-PIIINP) levels (P = .005), left ventricular ejection fraction (LVEF) (P = .0002), and a restrictive mitral filling pattern (P = .0003) predicted event-free survival. At the multivariate analysis, p-PIIINP levels predicted outcome independently of other clinical variables, hormones, and echocardiographic and exercise testing variables (P < .05 in all models). In patients with LVEF <31%, the presence of p-PIIINP >4.7 microg/L levels was significantly associated with a higher risk of death and hospitalization as compared with the other patients (event-free survival rate at 12 months: 45% versus 95%; at 24 months: 27% versus 88%; at 36 months: 18% versus 85%, P < .0001). CONCLUSIONS: In patients with CHF, PIIINP levels predict outcome independently of clinical status, hemodynamics and hormonal activation. PIIINP levels provide additional prognostic information to that of left ventricular function alone, suggesting that it may reflect more than cardiac extracellular matrix turnover. 相似文献
109.
110.
De Berardis G Pellegrini F Franciosi M Belfiglio M Di Nardo B Greenfield S Kaplan SH Rossi MC Sacco M Tognoni G Valentini M Nicolucci A;QuED 《Nutrition, metabolism, and cardiovascular diseases : NMCD》2008,18(1):57-65
Background and aimIn the context of the QuED Study we assessed whether a quality of care summary score was able to predict the development of cardiovascular (CV) events in patients with type 2 diabetes.Methods and resultsThe score was calculated using process and intermediate outcome indicators (HbA1c, blood pressure, low-density lipoprotein cholesterol, microalbuminuria) and ranged from 0 to 40. Overall, 3235 patients were enrolled, of whom 492 developed a CV event after a median follow-up of 5 years. The incidence rate (per 1000 person-years) of CV events was 62.4 in patients with a score ≤10, 54.8 in those with a score between 15 and 20, and 39.8 in those with a score >20. In adjusted multilevel regression models, the risk to develop a CV event was 89% greater in patients with a score of ≤10 (rate ratio [RR] = 1.89; 95% confidence interval [CI] 1.43–2.50) and 43% higher in those with a score between 10 and 20 (RR = 1.43; 95% CI 1.14–1.79), as compared to those with a score >20. A difference between centers of 5 points in the mean quality score was associated with a difference of 16% in CV event risk (RR = 0.84; 95% CI 0.72–0.98).ConclusionOur study documented for the first time a close relationship between a score of quality of diabetes care and long-term outcomes. 相似文献